## Management of Bilateral Retinoblastoma with Germline Mutation ### Clinical Context: Hereditary Bilateral Disease **Key Point:** Bilateral retinoblastoma accounts for 25–30% of all retinoblastoma cases and is almost always hereditary (germline RB1 mutation). The presence of a germline mutation means both eyes are at risk, and the goal is to preserve vision in at least one eye while achieving disease control. ### Why Systemic Chemotherapy is the Standard of Care | Aspect | Rationale | |--------|----------| | **Germline mutation** | Indicates hereditary disease with bilateral risk; both eyes must be treated | | **Vitreous seeding in left eye** | ICRB Group C or D; requires systemic therapy for disease control | | **Smaller mass in right eye** | ICRB Group A or B; potentially salvageable with focal therapy after chemotherapy | | **Normal IOP** | Indicates no secondary glaucoma; eyes are still salvageable | | **Age 3 years** | Young enough to benefit from globe-salvaging therapy; long life expectancy | ### Treatment Algorithm for Bilateral Retinoblastoma ```mermaid flowchart TD A[Bilateral Retinoblastoma + Germline RB1 Mutation]:::outcome --> B[Systemic Chemotherapy]:::action B --> C[Induction Phase: 4-6 cycles of chemotherapy]:::action C --> D[Response Assessment: Imaging + Fundoscopy]:::decision D -->|Good response| E[Focal Therapy: Laser/Cryotherapy/Brachytherapy]:::action D -->|Partial response| F[Repeat chemotherapy or intensify focal therapy]:::action D -->|Poor response| G[Consider enucleation of affected eye]:::urgent E --> H[Intensive surveillance: Every 4-6 weeks]:::action F --> H G --> I[Histopathology + Adjuvant therapy if high-risk]:::action H --> J[Long-term follow-up: Assess vision, screen contralateral eye]:::action ``` ### Chemotherapy Regimens **High-Yield:** Standard systemic chemotherapy for retinoblastoma uses **intra-arterial chemotherapy (IAC)** or **intravenous chemotherapy (IVC)**: - **Intra-arterial chemotherapy (IAC):** Melphalan, cisplatin, topotecan delivered directly to the ophthalmic artery via selective catheterization. Used for ICRB Groups C–E. - **Intravenous chemotherapy (IVC):** Vincristine, etoposide, carboplatin. Used as induction therapy or for systemic disease. - **Typical regimen:** 4–6 cycles of chemotherapy followed by focal therapy (laser, cryotherapy, or brachytherapy) for residual disease. ### Focal Therapy After Chemotherapy **Clinical Pearl:** Focal therapy is applied AFTER systemic chemotherapy to treat residual disease: - **Laser photocoagulation:** For small tumours (< 3 mm) - **Cryotherapy:** For tumours at or near the optic disc or macula - **Brachytherapy:** For larger tumours or those with vitreous seeding - **External beam radiotherapy (EBRT):** Avoided in young children due to risk of secondary malignancy and orbital deformity ### Why Each Option is Correct or Incorrect | Option | Assessment | |--------|------------| | **Bilateral enucleation** | Incorrect — both eyes are still salvageable with chemotherapy and focal therapy. Enucleation is reserved for eyes with no light perception (Group E) or those that fail to respond to chemotherapy. | | **Systemic chemotherapy + focal therapy + surveillance** | **CORRECT** — Standard of care for bilateral hereditary retinoblastoma. Preserves vision in at least one eye while achieving disease control. | | **Observation with serial imaging only** | Incorrect — Vitreous seeding in the left eye indicates advanced disease (ICRB Group C or D) that will progress without treatment. Observation alone leads to loss of vision and life-threatening complications. | | **Right eye focal therapy + left eye enucleation** | Incorrect — Enucleation of the left eye is premature. The left eye should first receive systemic chemotherapy to assess response before deciding on focal therapy or enucleation. | ### Prognosis & Outcomes **High-Yield:** With modern multimodal therapy: - **Unilateral disease:** > 95% cure rate; vision salvage in 70–80% of cases - **Bilateral disease:** 90% cure rate; at least one eye salvaged in 70% of cases - **Germline mutation carriers:** Require lifelong surveillance for secondary malignancies (osteosarcoma, soft tissue sarcoma, melanoma) and contralateral eye disease ### Genetic Counselling **Key Point:** The presence of a germline RB1 mutation means: - **50% risk** of transmission to offspring - **Asymptomatic mother** has normal eye examination but may carry a germline mutation (incomplete penetrance or mosaicism); genetic testing is recommended - Siblings should undergo ophthalmologic screening every 6 weeks until age 5 ### Follow-up Schedule - **During treatment:** Every 2–4 weeks - **After treatment completion:** Every 4–6 weeks for 2 years, then every 3 months for 3 years, then every 6 months - **Lifelong surveillance:** Annual eye examination and systemic screening for secondary malignancies ### Mnemonic: BILATERAL RB Management **Mnemonic:** **CHEMO-FOCAL** - **C**hemotherapy (systemic, intra-arterial preferred) - **H**ereditary (germline RB1 mutation) - **E**ye salvage (goal) - **M**ultimodal therapy - **O**ncology involvement - **F**ocal therapy (laser, cryo, brachy) - **O**phthalmic surveillance - **C**ontralateral eye monitoring - **A**djuvant therapy if needed - **L**ifelong follow-up 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.